The UK and US have signed a major commercial pact that will ensure zero duties on British pharmaceutical shipments going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the NHS. This commitment ensures that tariffs on these crucial products will be held at nothing for a timeframe of three years.
This deal follows recent threats to significantly raise tariffs on branded drug imports, with increases floated as high as double the cost.
"This deal between the United Kingdom strengthens the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. medicine commerce," an announcement said.
Commercial Impact
Pharmaceuticals represent one of the Britain's most significant goods shipped to the United States, which is clearly the biggest destination for major UK drugmakers.
Statistics reveal that in the 12 months leading up to September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This deal protects work, stimulates investment and facilitates the UK to become a international leader for medical research," a government official commented.
Specific UK Commitments
The pact entails several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to double overall public funding on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. In the past, refunds were more than 20%.
Industry Background
The pact takes place against a protracted row between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were intensified by assertions that American patients were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while major investments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the past decade.
